Lilly cancer drug hits hurdle, panel recommends study continue

(Reuters) – An independent panel’s interim analysis of Eli Lilly and Co’s breast cancer drug abemaciclib showed the treatment did not meet the effectiveness criteria in a late-stage trial. If approved, abemaciclib is expected to compete with Pfizer Inc’s breast cancer drug, Ibrance, which brought in over half a billion dollars in second-quarter sales. The trial is designed to evaluate the safety and efficacy of abemaciclib, in combination with anti-estrogen drug fulvestrant, in patients with a form of advanced breast cancer.
Go to Source